Profile: Celsion Corporation is an innovative oncology drug development company singularly focused on improving treatment for those suffering with highly difficult forms of cancer. We are working to develop and commercialize more efficient, effective, targeted chemotherapeutic treatments based on our unique heat-activated liposomal technology. Our method is an elegant approach that delivers high concentrations of anti-cancer agents directly to the tumor site. Our pipeline of proven chemotherapeutics enhanced with low temperature sensitive liposome (LTSL) includes docetaxel (in preclinical development) and platinum (in formulation development). Our ThermoDox is an investigational new drug for both hepatocellular carcinoma (HCC, or primary liver cancer) and recurrent breast cancer at the chest wall (RCW). Our ThermoDox treatment approach is designed to deliver high concentrations of anti-cancer drugs directly to those cancer cells that survive radio frequency ablation (RFA). RFA ablates the center of the tumor and simultaneously activates ThermoDox to release its encapsulated doxorubicin, killing the remaining viable cancer cells throughout the heated region, including the tumor margins.

The company was founded in 1982, has revenues of < USD 1 Million, has ~30 employees and is ISO 9002, CE certified. AMEX:CLN (SEC Filings)